Major pharma eyes mid-priced biotech M&A deals in 2013

01/11/2013 | Xconomy

Big drugmakers with expired patents on major products will increasingly depend on mergers and acquisitions to increase sales, according to an analysis from Ernst & Young. Demand is expected to be high for biotech firms in the $5 billion to $20 billion range, particularly for "bolt-on" operations that can contribute to sales immediately.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX